Search Results - Baladi, JF

  • Showing 1 - 15 results of 15
Refine Results
  1. 1
    PSY15 ECONOMIC IMPLICATIONS OF IRON CHELATION IN PATIENTS WITH REFRACTORY ANEMIA RELATED TO MYELODYSPLASTIC SYNDROME

    PSY15 ECONOMIC IMPLICATIONS OF IRON CHELATION IN PATIENTS WITH REFRACTORY ANEMIA RELATED TO MYELODYSPLASTIC SYNDROME by Migliaccio-Walle, K, Baladi, JF

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    PHM8 THE POTENTIAL IMPACT OF CHELATION THERAPY (CT) ON THE QUALITY OF LIFE (QOL) OF PATIENTS WITH IRON OVERLOAD (IO)

    PHM8 THE POTENTIAL IMPACT OF CHELATION THERAPY (CT) ON THE QUALITY OF LIFE (QOL) OF PATIENTS WITH IRON OVERLOAD (IO) by Abetz, L, Jones, P, Baladi, JF

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    PMC27 THE DEVELOPMENT OF A TREATMENT SATISFACTION QUESTIONNAIRE FOR IRON OVERLOAD (IO) PATIENTS ON CHELATION THERAPY (CT)

    PMC27 THE DEVELOPMENT OF A TREATMENT SATISFACTION QUESTIONNAIRE FOR IRON OVERLOAD (IO) PATIENTS ON CHELATION THERAPY (CT) by Abetz, L, Baladi, JF, Jones, P, Rofail, D

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    The economic evaluation of pharmacotherapies for Parkinson's disease

    The economic evaluation of pharmacotherapies for Parkinson's disease by Coyle, D., Barbeau, M., Guttman, M., Baladi, J.-F.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    PCN2 COST-EFFECTIVENESS OF IMATINIB (GLEEVEC)AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

    PCN2 COST-EFFECTIVENESS OF IMATINIB (GLEEVEC)AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML) by El Ouagari, K, Talbot, W, Baladi, JF

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    PNP17 COMPLIANCE OF TWO TREATMENTS OF ALZHEIMER'S DISEASE

    PNP17 COMPLIANCE OF TWO TREATMENTS OF ALZHEIMER'S DISEASE by Barbeau, M, Baladi, JF

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    PHM4 COSTS AND CONSEQUENCES OF INADEQUATE COMPLIANCE WITH DEFEROXAMINE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA

    PHM4 COSTS AND CONSEQUENCES OF INADEQUATE COMPLIANCE WITH DEFEROXAMINE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA by Delea, T, Sofrygin, O, Thomas, S, Baladi, JF, Coates, TD, Phatak, P

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    PHM1 COST-EFFECTIVENESS OF ONCE-DAILY ORAL CHELATION THERAPY WITH DEFERASIROX VERSUS INFUSIONAL DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS

    PHM1 COST-EFFECTIVENESS OF ONCE-DAILY ORAL CHELATION THERAPY WITH DEFERASIROX VERSUS INFUSIONAL DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS by Delea, T, Sofrygin, O, Thomas, S, Baladi, JF, Phatak, P, Coates, TD

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals

    The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals by Glennie, J L, Torrance, G W, Baladi, J F, Berka, C, Hubbard, E, Menon, D, Otten, N, Rivière, M

    Published in PharmacoEconomics
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  10. 10
    PHP15: IMPACT OF FIRST GENERIC ENTRANTS ON BRAND NAME PRODUCTS

    PHP15: IMPACT OF FIRST GENERIC ENTRANTS ON BRAND NAME PRODUCTS by Kleinstiver, P, Baladi, JF

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    PSY53 SATISFACTION WITH IRON CHELATION THERAPY IS ASSOCIATED WITH IMPROVED QUALITY OF LIFE IN PATIENTS WITH IRON OVERLOAD

    PSY53 SATISFACTION WITH IRON CHELATION THERAPY IS ASSOCIATED WITH IMPROVED QUALITY OF LIFE IN PATIENTS WITH IRON OVERLOAD by Rofail, D, Abetz, L, Heelis, R, Baladi, JF

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  12. 12
    Rivastigmine for alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications

    Rivastigmine for alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications by Baladi, Jean-François, Bailey, Peter A.B., Black, Sandra, Bouchard, Rémi W., Farcnik, Karl D., Gauthier, Serge, Kertesz, Andrew, Mohr, Erich, Robillard, Alain

    Published in Clinical therapeutics
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  13. 13
    PMT13: TRANSFERING THE RESULTS FROM ECONOMIC EVALUATIONS: THE USE OF BASILIXIMAB IN TRANSPLANT PATIENTS

    PMT13: TRANSFERING THE RESULTS FROM ECONOMIC EVALUATIONS: THE USE OF BASILIXIMAB IN TRANSPLANT PATIENTS by Lee, KM, Coyle, D, Baladi, JF

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  14. 14
    MGA6 Survey Strategies in the Revision of the Guidelines for Economic Evaluation: Canada

    MGA6 Survey Strategies in the Revision of the Guidelines for Economic Evaluation: Canada by Glennie, JL, Baladi, JF, Berka, C, Hubbard, E, Menon, D, Otten, N, Riviere, M, Torrance, G

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Stability characteristics of a single-phase free convection loop

    Stability characteristics of a single-phase free convection loop by Creveling, H. F., De Paz, J. F., Baladi, J. Y., Schoenhals, R. J.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: